Novo Nordisk Pharmatech A/S brings new recombinant insulin to BioPharma Asia in Singapore

Koege , Denmark:- Leading Danish supplier of recombinant insulin , Novo Nordisk Pharmatech A/S , will be exhibiting its product line at one of South East Asia’s premier industry events, the BioPharma Asia Convention in Singapore.

The Novo Nordisk Pharmatech team on stand B12 at the Suntec Convention Center in Singapore will be showcasing the company’s recombinant insulin as a key component in serum free growth media for mammalian cells.

Novo Nordisk Pharmatech is one of the world’s leading suppliers of recombinant insulin in cell culture media, powering biopharma blockbuster drugs worldwide.

Optimized cell line media

“This recombinant insulin can be used for the manufacturing of monoclonal antibodies, virus vaccines, gene therapy products and many other biological drug products approved by regulatory bodies worldwide, including FDA and EMA,” said Magnus, Product manager for Novo Nordisk Pharmatech recombinant insulin product.

“This event gives us a great opportunity to focus on our growing Asian market and in particular to reach out to Asian-based biopharmaceutical companies working in cell line development who want to enhance and optimize their cell line media growth. Our insulin can help them achieve this,” Mr. Franzmann explained.

Insulin quality

“For researchers and upstream production managers looking to optimize cell density and viability, insulin quality can play an important role in cell culture media,” he added.

“Biosimilar manufacturers need to keep a strong focus on the manufacturing process of originator drugs. Using Novo Nordisk recombinant insulin reduces the risk of deviations when substituting or replacing insulin in the process,” said Franzmann, who will be part of the Novo Nordisk stand team, on hand to answer technical questions.

Visitors to the stand will also have an opportunity to enter a competition to win an Amazon Kindle.

The stand will also be showing the company’s newest report on Optimization of CHO-S cell culture medium by supplementation with non-animal derived components using DoE –

About Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, acquired by Novo Nordisk in 1986 and has been part of the pharmaceutical group since then. On 1 September 2015 the company’s name was changed to Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries

The company markets its diabetic care, hemophilia, growth hormone therapy, obesity, and hormone replacement therapy (HRT) products worldwide, with customers in more than 180 countries.

For Financial Year 2015, Novo Nordisk reported world sales totaling 107,927 million Danish kroner (DEK) with more than half of all sales recorded in North America.

About Biopharma Asia 2016

The BioPharma Asia Convention bills itself as Asia’s most important biopharmaceutical gathering, currently attracting some 2,000 attendees annually, along with more than 100 exhibiting companies.

Since its founding as BioMedical Asia in 2008, BioPharma Asia Convention has attracted close to 20,000 attendees over the past eight years. The core focus of the event remains to explore the tapped and untapped markets of Asia and present the progress of Asia’s biopharmaceutical industries.

The BioPharma Asia Convention 2016 is a three-day event opening March 22 at the Suntec Singapore International Exhibition and Convention Centre.

The 2016 convention will feature an expanded program with separate conference tracks, including innovation in clinical trials, manufacturing, supply chain, market access, partnering, pricing, vaccines and infectious diseases, antibodies, orphan drugs, biosimilars, and stem cell research.

The event is organized by Terrapinn Pte. Ltd with more information at:
http://www.terrapinn.com/exhibition/bio-asia/index.stm